Document is current
Any future updates will be listed below
-
Authors
Fassunke, Jana
Müller, Fabienne
Keul, Marina
Michels, Sebastian
Dammert, Marcel A.
Schmitt, Anna
Plenker, Dennis https://orcid.org/0000-0003-3895-4064
Lategahn, Jonas
Heydt, Carina
Brägelmann, Johannes
Tumbrink, Hannah L.
Alber, Yannic
Klein, Sebastian
Heimsoeth, Alena
Dahmen, Ilona
Fischer, Rieke N.
Scheffler, Matthias
Ihle, Michaela A.
Priesner, Vanessa
Scheel, Andreas H. https://orcid.org/0000-0003-0244-1646
Wagener, Svenja
Kron, Anna
Frank, Konrad
Garbert, Katia
Persigehl, Thorsten
Püsken, Michael
Haneder, Stefan
Schaaf, Bernhard
Rodermann, Ernst
Engel-Riedel, Walburga
Felip, Enriqueta
Smit, Egbert F.
Merkelbach-Bruse, Sabine
Reinhardt, H. Christian
Kast, Stefan M. https://orcid.org/0000-0001-7346-7064
Wolf, Jürgen
Rauh, Daniel https://orcid.org/0000-0002-1970-7642
Büttner, Reinhard
Sos, Martin L.
- License Information
-
More Information
Article History
Received: 14 March 2018
Accepted: 12 September 2018
First Online: 7 November 2018
Competing interests
: J.F. and C.H. received speaking honoraria from AstraZeneca; R.N.F. received speaking honoraria from Bristol-Myers Squibb, MSD, Roche, Boehringer Ingelheim, consulting fees from Bristol-Myers Squibb, Roche and funding for scientific research from Bristol-Myers Squibb, MSD; M.S. received lecturer fees from AstraZeneca, lecturer, and consulting fees from Boehringer Ingelheim and consulting fees from Novartis; V.P. has received congress fees, travel fees, and accommodation from Novartis, Boehringer Ingelheim, Gilead, BMS; A.H.S. has participated in advisory boards for Bristol-Myers Squibb, Roche Pharma, and Merck Sharp & Dohme within the past 12 months; H.C.R. received consulting and lecture fees from Abbvie, Astra-Zeneca, Vertex and Merck, and received research funding from Gilead Pharmaceuticals; E.R. has received speaking honoraria from Celgene and received consulting fees from Novartis and BMS; E.F. has previously acted in a consulting or advisory role or speaker’s bureau for: AstraZeneca, Boehringer Ingelheim, Brisol–Myers Squibb, Celgene, Eli Lilly, Guardanthealth, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Takeda; S.M.-B. received speaking honoraria from AstraZeneca; J.W. received consulting and lecture fees from Abbvie, AstraZeneca, BMS, Boehringer Ingelheim, Chugai, Ignyta, Lilly, MSD, Novartis, Pfizer, Roche, and funding for scientific research from BMS, Johnson&Johnson, MSD, Novartis, Pfizer; D.R. received consultant and lecture fees from Astra-Zeneca, Merck-Serono, Takeda, Pfizer, Novartis, Boehringer Ingelheim, and Sanofi-Aventis; R.B. is an employee of Targos Molecular Pathology; M.L.S. received a commercial research grant from Novartis.The remaining authors declare no competing interests.
